Alabama Pauses Automatic Marijuana Rescheduling After Federal Order

Alabama’s public health governing body has formally hit pause on an automatic state marijuana rescheduling, voting unanimously on May 22, 2026, to object to the federal government’s April reclassification before it triggered an automatic state-level change — opening a 30 to 60 day public hearing window that gives the state time to work through the implications for its medical cannabis program.

How Alabama’s scheduling mirror works

Under Alabama’s controlled substances law, whenever the federal government reclassifies a controlled substance, the state automatically mirrors that change within 30 days of the Federal Register publication — unless the State Board of Health formally objects. An objection doesn’t block rescheduling permanently; it stays the automatic change and opens a mandatory public comment and hearing process, after which the Board publishes a binding decision.

The governing body of the Alabama Department of Public Health laid out three options at its meeting: no objection would mean immediate scheduling; silence, the automatic 30-day mirror; or a formal objection, which buys time for stakeholder consultation. State Health Officer Dr. Scott Harris made the case for the third path.

“If you receive it without objection, it’s scheduled immediately,” Harris said. “I’m going to ask you to take the third option, which is to object. Then we just have a little bit of time to figure this out with all of our other stakeholders.”

The committee voted unanimously to object. ADPH chief legal officer Brian Hale said the objection activates a 30 to 60 day public comment period and a public hearing, during which the department will consult with licensing boards and others with a stake in how marijuana is classified under state law.

What’s at stake for Alabama’s medical program

The federal trigger was Acting Attorney General Todd Blanche’s order of April 23, 2026, which placed both FDA-approved marijuana products and state-licensed medical marijuana in Schedule III of the federal Controlled Substances Act. The same order launched an administrative hearing beginning June 29, 2026, to consider broader rescheduling of all marijuana — completing the process President Trump set in motion with a December 2025 executive order directing the Justice Department to expedite the reclassification.

For states with operating medical programs, the shift in federal scheduling status carries tangible consequences. Reclassifying to Schedule III should allow medical operators to deduct ordinary business expenses that the federal cannabis tax penalty had previously barred — a change that directly improves the economics for licensed dispensaries. Researchers also stand to gain access to state-licensed products for clinical study, ending a longtime restriction to federally grown supply that had severely limited the scope of cannabis research.

Alabama passed its medical cannabis law in 2021. The Alabama Medical Cannabis Commission has been building out its licensing infrastructure ever since, and state reporting indicated the state’s first dispensary was preparing to open as of late May 2026. Harris said the federal rescheduling would not conflict with state law, but that understanding how the federal change intersects with Alabama’s existing regulatory structure required more analysis than the 30-day automatic window would allow.

Not opposition — deliberation

Despite the pause, state officials were unambiguous: Alabama intends to implement the rescheduling. Harris told the committee the state “fully intends” to complete the process; the Board’s objection is a mechanism for structured input, not a challenge to the underlying direction.

The Alabama Medical Cannabis Commission echoed that position. General counsel Justin Aday said the commission does not anticipate immediate operational impact from either the federal order or the state-level delay, and expects to participate in the upcoming comment and hearing process.

Once the Board of Health concludes its public hearing and publishes a decision, that determination is final under state law unless the legislature acts to change it. The formal objection holds the 30-day clock; the rescheduling itself remains on a path toward implementation.

Alabama is not alone in navigating this kind of federal-state sequencing. Several states have similar automatic mirror provisions in their controlled substances statutes, meaning the April federal order has set off parallel scheduling reviews in multiple capitals. The broader federal picture is still contested: a House appropriations subcommittee recently advanced a funding rider that would block the federal rescheduling proceeding, and operators working through DEA registration requirements — which the agency has been extending to the full supply chain — face a layered set of timelines ahead of the June 29, 2026 administrative hearing.